Medicentrum Beroun a.s.
- Address
- Politickych Veznu 40, 266 01 Beroun-Mesto, Czechia
Cardiovascular Diseases
The department is testing evolocumab to see if it can lower the risk of coronary heart disease, heart attack and stroke in adults at high cardiovascular risk, and also evaluating maridebart cafraglutide as an add‑on therapy for patients with atherosclerotic disease who are overweight or obese.
- Risk reduction for coronary heart disease, myocardial infarction, and ischemic stroke
- Impact of novel lipid‑lowering therapy on cardiovascular outcomes
- Adjunctive therapy for atherosclerotic disease in overweight patients
Medicentrum Beroun a.s. is contributing to advances in heart health through these studies.
Hemic and Lymphatic Diseases
Researchers are comparing efepoetin alfa with darbepoetin alfa to improve anemia management in chronic kidney disease patients receiving dialysis, aiming for better hemoglobin control.
- Management of anemia in chronic kidney disease
- Hemoglobin level control in dialysis patients
- Comparative effectiveness of erythropoiesis‑stimulating agents
The Dialýza a.s. department leads these efforts to enhance patient quality of life.
Nutritional and Metabolic Diseases
A study is investigating how a GLP‑1‑based agent can reduce cardiovascular events while also supporting weight loss in participants with atherosclerotic disease and obesity or excess weight, addressing metabolic risk factors.
- Weight management in cardiovascular risk populations
- Metabolic syndrome and cardiovascular outcomes
- Use of GLP‑1 receptor agonists for dual benefit
Ongoing research aims to link metabolic health improvements with better heart outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Amgen Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medicentrum Beroun a.s.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Darbepoetin Alfa | 1 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.